Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8535331rdf:typepubmed:Citationlld:pubmed
pubmed-article:8535331lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:8535331lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:8535331lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:8535331lifeskim:mentionsumls-concept:C1657587lld:lifeskim
pubmed-article:8535331lifeskim:mentionsumls-concept:C0871161lld:lifeskim
pubmed-article:8535331lifeskim:mentionsumls-concept:C0385323lld:lifeskim
pubmed-article:8535331lifeskim:mentionsumls-concept:C0599278lld:lifeskim
pubmed-article:8535331pubmed:issue6lld:pubmed
pubmed-article:8535331pubmed:dateCreated1996-2-8lld:pubmed
pubmed-article:8535331pubmed:abstractTextThe tritiated dopamine reuptake inhibitor [3H]NNC 12-0781 ([1-[2-(bis(4-fluorophenyl)-methoxy)-ethyl]-4-(3-(2-furanyl)-2,3-[3H] - propyl)-piperazine) was radiolabelled in one step starting from 1-[2-(bis(4-fluorophenyl)-methoxy)-ethyl]-4-(3-(2-furanyl)-2-propenyl)- piperazine, using tritium gas and PdO as catalyst. The radiochemical purity of [3H]NNC 12-0781 was higher than 99% after HPLC purification with a specific radioactivity of 21 Ci/mmol. [3H]NNC 12-0781 bound specifically to rat striatum in vitro at +4 degrees C with a Kd of 1.76 nM and Bmax of 587 fmol/mg tissue. The nonspecific binding was about 10% at Kd. At +37 degrees C no acceptable binding was observed. The association of [3H]NNC 12-0781 thus has the characteristics of a radioligand for the dopamine transporter in vitro at +4 degrees C.lld:pubmed
pubmed-article:8535331pubmed:languageenglld:pubmed
pubmed-article:8535331pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8535331pubmed:citationSubsetIMlld:pubmed
pubmed-article:8535331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8535331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8535331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8535331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8535331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8535331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8535331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8535331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8535331pubmed:statusMEDLINElld:pubmed
pubmed-article:8535331pubmed:monthAuglld:pubmed
pubmed-article:8535331pubmed:issn0969-8051lld:pubmed
pubmed-article:8535331pubmed:authorpubmed-author:HallHHlld:pubmed
pubmed-article:8535331pubmed:authorpubmed-author:NielsenE BEBlld:pubmed
pubmed-article:8535331pubmed:authorpubmed-author:MüllerLLlld:pubmed
pubmed-article:8535331pubmed:authorpubmed-author:FardeLLlld:pubmed
pubmed-article:8535331pubmed:authorpubmed-author:SuzdakP DPDlld:pubmed
pubmed-article:8535331pubmed:authorpubmed-author:HalldinCClld:pubmed
pubmed-article:8535331pubmed:authorpubmed-author:HohlwegRRlld:pubmed
pubmed-article:8535331pubmed:authorpubmed-author:FogedCClld:pubmed
pubmed-article:8535331pubmed:issnTypePrintlld:pubmed
pubmed-article:8535331pubmed:volume22lld:pubmed
pubmed-article:8535331pubmed:ownerNLMlld:pubmed
pubmed-article:8535331pubmed:authorsCompleteYlld:pubmed
pubmed-article:8535331pubmed:pagination711-7lld:pubmed
pubmed-article:8535331pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:meshHeadingpubmed-meshheading:8535331-...lld:pubmed
pubmed-article:8535331pubmed:year1995lld:pubmed
pubmed-article:8535331pubmed:articleTitleSynthesis and binding properties of [3H]NNC 12-0781, a new radioligand for the dopamine reuptake system.lld:pubmed
pubmed-article:8535331pubmed:affiliationNovo Nordisk A/S, Pharmaceuticals Division, Maaloev, Denmark.lld:pubmed
pubmed-article:8535331pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8535331pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed